UroGen Pharma Ltd
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
URGN$25.32-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash Flows From Operating Activities | ||
| Net loss | $(102,244) | $(109,783) |
| Adjustment to reconcile net loss to net cash from operating activities: | ||
| Depreciation and amortization | 802 | 924 |
| Inventory Obsolescence | — | 870 |
| Accrued financing on prepaid forward obligation | 11,504 | 14,007 |
| (Accretion) on marketable securities | (1,034) | (498) |
| Share-based compensation | 9,343 | 10,580 |
| Amortization (accretion) of discount on long-term debt | 1,014 | 1,754 |
| Amortization of right-of-use assets | 903 | 893 |
| Changes in operating assets and liabilities: | ||
| Inventory | (1,348) | (362) |
| Accounts receivable | (2,739) | (987) |
| Prepaid expenses and other current assets | 820 | (3,626) |
| Other non-current assets | 702 | (1,269) |
| Accounts payable and accrued expenses | 4,155 | 281 |
| Employee related accrued expenses | 2,557 | 1,309 |
| Other current liabilities | — | (703) |
| Lease liabilities | (987) | (1,125) |
| Uncertain tax positions | 176 | 176 |
| Net cash used in operating activities | (76,376) | (87,559) |
| Cash Flows From Investing Activities | ||
| Purchases of marketable securities | (49,832) | (63,009) |
| Maturities of marketable securities | 49,073 | 64,323 |
| Purchases of property and equipment | (194) | (254) |
| Net cash (used in) provided by investing activities | (953) | 1,060 |
| Cash Flows From Financing Activities | ||
| Proceeds from exercise of options into ordinary shares | 873 | 1,511 |
| Proceeds from issuance of long-term debt | — | 95,783 |
| Proceeds from pre-funded warrant issuance, net of $1,654 of issuance costs | 48,700 | — |
| Proceeds from ordinary share issuance, net of $2,288 of issuance costs | 67,358 | — |
| Issuance cost related to at-the-market issuances | — | (160) |
| Net cash provided by financing activities | 116,931 | 97,134 |
| Increase in Cash and Cash Equivalents | 39,602 | 10,635 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year | 56,221 | 45,586 |
| Cash, Cash Equivalents and Restricted Cash at End of Year | $95,823 | $56,221 |
| Supplemental Disclosures of Non-Cash Activities | ||
| Right-of-use assets obtained in exchange for new operating lease liabilities | $122 | $2,165 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.